drugset / Trial / NCT01635127
Efficacy Study of Canakinumab to Treat Urticaria
RandomizedCrossoverQuadruple-blindTreatment
Summary
Evaluation whether canakinumab leads to improvement of urticaria
Timeline
- Start
- 2012-06
- Primary completion
- 2016-12
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 150 mg | Subcutaneous |